Related Experiment Video
Updated: Jun 4, 2026

Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
Drotrecogin alpha: a rational approach to the treatment of submassive pulmonary embolism?
Charles Marc Samama1, Anne Godier
1Department of Anaesthesiology and Intensive Care Medicine, Hotel-Dieu University Hospital, 1, place du Parvis de Notre-Dame, 75181 Paris Cedex 04, France. marc.samama@htd.aphp.fr
Combining therapeutic doses of low-molecular-weight heparins and increasing doses of recombinant activated protein C - Drotrecogin alpha (activated), or DAA - is of theoretical interest with regard to the control of coagulation activation. The study by Dempfle and colleagues presents new data showing that endogenous activated protein C levels do not increase in nonseptic patients with pulmonary embolism. However, the results of the addition of these two treatments are puzzling, leaving unresolved the questionable clinical relevance of this combination and the possible increase in bleeding risk.
Combining therapeutic doses of low-molecular-weight heparins and increasing doses of recombinant activated protein C - Drotrecogin alpha (activated), or DAA - is of theoretical interest with regard to the control of coagulation activation. The study by Dempfle and colleagues presents new data showing that endogenous activated protein C levels do not increase in nonseptic patients with pulmonary embolism. However, the results of the addition of these two treatments are puzzling, leaving unresolved the questionable clinical relevance of this combination and the possible increase in bleeding risk.
Related Concept Videos
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism III: Nursing Management
Pulmonary Embolism I: Introduction
Pulmonary Embolism I: Introduction
Anticoagulant Drugs: Low-Molecular-Weight Heparins
